Columbia, Maryland, USA. - March 24, 2023 - Intralytix, Inc. today announced successful, full enrollment of its Phase 1 clinical trial at the University of Maryland's School of Medicine (UMSOM) in Baltimore under the direction of Dr. Wilbur Chen, Professor of Medicineand Chief of Adult Clinical Studies at UMSOM's Center for Vaccine Development and Global Health (CVD). The clinical trial is to assess the safety of Intralytix phage therapy product ShigActive™ intended to prevent or reduce the severity of Shigella infections. The trial is partially funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the NIH. This represents another advance towards realizing phage therapy for treatment and management of shigellosis, a bacterial disease of great public health importance.
About Intralytix Inc.
Intralytix, Inc. is a privately held company headquartered in Columbia, Maryland. The Company is focused on using its core bacteriophage technology platform to improve human health through the development and commercialization of innovative products for food safety, animal health, human therapeutics, oral care, cosmetic, and dietary supplements/probiotic applications. Intralytix was the first company in the world to receive FDA-approval for a bacteriophage-based product for food safety applications. The Company currently has the world's largest portfolio of FDA-approved bacteriophage-based products on commercial markets and is the largest producer of FDA-approved bacteriophage preparations for food safety applications worldwide. Intralytix is currently the sponsor of (and holder for) three FDA-approved Investigational New Drugs (INDs) for randomized, controlled clinical trials. The Company also has several additional human therapeutic bacteriophage products in various stages of development. To learn more, please visit www.intralytix.com or contact Dr. Alexander Sulakvelidze (410-625-2533, firstname.lastname@example.org).